Navigation Links
Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Date:5/22/2012

SUNNYVALE, Calif., May 22, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 17th Congress of the European Hematology Association (EHA), June 14-17, 2012 in Amsterdam, The Netherlands.

The update on data presented specifically includes: 1) updated safety and efficacy data, including progression free survival, from the phase Ib/II CLL single agent trial in relapsed or refractory and treatment naive patients (PCYC-1102-CA); 2) safety and efficacy data from the phase Ib CLL combination trial with bendamustine and rituximab in relapsed or refractory patients (PCYC-1108-CA). Pharmacyclics plans to issue a material update on the ibrutinib clinical development program and its results in a press release after the EHA oral presentations.

Oral Presentation at EHA, Amsterdam, The Netherlands (June 14-17, 2012)
Date/Time: Saturday, June 16, 2012; 8:00 AM – 8:15 AM CET
Location: Elicium 1
Abstract # 1970: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Relapsed or Refractory and Treatment Naive Chronic Lymphocytic Leukemia Patients, Updated Results of a Phase Ib/II Study.
Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas.

Oral Presentation at EHA, Amsterdam, The Netherlands (June 14-17, 2012)
Date/Time: Saturday, June 16, 2012; 8:15 AM – 8:30 AM CET
Location: Elicium 1
Abstract # 1590: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study.
Dr. Jennifer Brown et al. Dana-Farber Cancer Institute, Boston, Massachusetts.

Ibrutinib is an oral
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics to Host a Conference Call on March 15, 2012 to Discuss Second Quarter Fiscal 2012 Financial and Operational Results
3. Pharmacyclics Inc. Receives Issue Notice of Significant Brutons Tyrosine Kinase (BTK) Patent
4. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
5. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
6. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
7. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
8. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
9. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
10. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
11. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Sage Analytics ( www.sageanalytics.com ... laboratory-quality cannabis potency measurement systems, announced its sponsorship of ... Cruise Fundraiser. A limited number of tickets are available ... help a great cause while enjoying an open bar, ... around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, ... and development agreements between biotech companies, military ... biotech solutions & therapies with regards to ... to positive clinical enhancements for regenerative medicine ... with recent developments, partnerships and advancements in ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6
... 11 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... 6th Annual Healthcare Conference on Wednesday, November 18, at 8:30 ... may access a live webcast of the presentation on our ... It is recommended that listeners log on 15 minutes early ...
... NEW YORK, Nov. 11 Pulmo BioTech Inc. (OTC ... early experimental results have indicated that its PulmoBind(TM) product ... and follow-up of many conditions that affect the physical ... results, if confirmed by further experiments, would broaden the ...
Cached Medicine Technology:Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 2Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 3Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 4
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... the Atlanta Journal Constitution, the new Lifetime reality series, “Atlanta Plastic” is getting ... and who receives plastic surgery, with its predominantly African-American cast of doctors and ...
(Date:8/3/2015)... Los Angeles, California (PRWEB) , ... August 03, ... ... the Fifth Circuit Court of Appeals ruled in favor of the firm’s client ... Act ), North Cypress Medical Center must reimburse benefits for Hamsher’s residential treatment ...
(Date:8/3/2015)... Irving, Texas (PRWEB) , ... August 03, 2015 ... ... awarded an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and ... care and reduce health care costs. , Annually, more than 8.6 million ...
(Date:8/3/2015)... ... , ... Dental practice in Los Angeles , Sunset Plaza Dental, is ... general health emergencies, such as broken arms or a heart attack, should be evaluated ... to during a dental emergency. This is important, because dental trauma is extremely common. ...
(Date:8/3/2015)... Florida (PRWEB) , ... August 03, 2015 , ... ... for Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis ... , Fifty-five percent of respondents said they agreed or strongly agreed that the ...
Breaking Medicine News(10 mins):Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3
... near green spaces such as park and lawns in their ... said a US study. ,Researchers studied 7,334 children, ... and used body mass index to determine which children were ... green space and the number of food outlets such as ...
... perfect golf swing could lie in your big toe. Or your ... American College// of Foot and Ankle Surgeons (ACFAS) say these are ... that can ruin your golf swing. ,Behind these ... damage. But pain relief is possible and frequently does not require ...
... Administration ordered the makers of ADHD drugs to indicate the ... psychiatric and cardiovascular risks. ,Dr. Steven Galson, director ... that although these drugs are immensely useful in treating patients ... the public. He also said that FDA is working ...
... about that shared experience are likely more satisfied with ... of experience to draw on, according to research by ... ,The study, conducted by Doris G. Bazzini and three ... issue of the journal Motivation and Emotion. ...
... Some men who become impotent after prostate cancer surgery may ... into the penis,// which assists in restoring the lost erectile ... ,These findings came to light after a study of nearly ... restore erectile function, following its loss after treatment for prostate ...
... 30 years as the director of the Johns Hopkins Brady ... Faisal Foundation for his pioneering work in the area of ... the Saudi royal family and director of the King Faisal ... Prize at an awards ceremony in Riyadh on Jan. 16. ...
Cached Medicine News:Health News:Foot Pain Ruining Your Golf Swing? 2Health News:Researcher Studies Benefits of Reminiscing About Laughter 2Health News:Patrick Walsh Wins International Medicine Prize 2
... is one of the world's ... with a 7 F introducer, ... is designed to lower the ... allow introduction in smaller, more ...
... The Model 6491 unipolar ... designed for temporary atrial and ... and after cardiac surgery. This ... downsized, making it the ideal ...
The CapSureFix line of pacing leads combines the benefits of steroid-eluting technology with screw-in active fixation, to allow long-lasting, low-threshold delivery of pacing therapies....
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Medicine Products: